Bitwise CIO Matt Hougan highlights Bitcoin's decreasing volatility—from 66% over the past decade to 44% in the last year—as evidence of its maturation into digital gold. Despite still being volatile compared to traditional assets like the Nasdaq-100, Hougan forecasts Bitcoin's volatility could fall below that of major tech stocks as institutional adoption grows. This trend suggests Bitcoin is transitioning from a speculative asset to a more stable store of value, potentially increasing its appeal to institutional investors who allocate based on risk. Investors should watch Bitcoin's volatility relative to the Nasdaq-100 to gauge this progress.
The story on Bitwise CIO Matt Hougan's view of Bitcoin's maturing volatility is offered here alongside Pluang's cryptocurrency market snapshot. As of Oct 07, 2026 04:41 WIB, out of 50 major cryptocurrencies priced on Pluang, only 9 rose while 40 fell. Among notable movers, SAND dropped 4.02% to Rp1.184 with a typical hold time of 123 days and a 63% sell order activity, contrasting with ZIL which fell 3.81% to Rp63 but had a 72% buy order activity and a longer hold time of 133 days. CRV also declined 3.52% to Rp6.488 with a balanced sell/buy split and a shorter hold time of 62 days.
Constellation Brands reported earnings per share of $3.74, surpassing analyst estimates of $3.55, and revenue of $2.63 billion, exceeding the $2.54 billion forecast. The company saw a 5% increase in beer sales and a 17% rise in wine and spirits sales...
Tilray Brands will announce its fiscal Q1 2027 earnings on October 8, with analysts forecasting a loss of $0.16-$0.19 per share on revenues around $265-$268 million, marking about 26% growth from last year. Investors will focus on cannabis and bevera...
On October 6, 2026, five notable stocks surged between 20.9% and 52.7%, driven by various positive developments. Apimeds Pharmaceuticals rose 52.7% after its subsidiary signed a blockchain contract, while Option Care Health gained 32.7% following a $...
On October 6, five notable stocks saw significant declines, with losses ranging from 17.5% to 50.1%. ArriVent BioPharma's shares plunged 46.9% after its lung cancer treatment failed to meet the primary endpoint in a Phase 3 trial. Armada Acquisition ...
Evercore ISI raised its price target for Marvell Technology to $433 from $275, maintaining an Outperform rating. This follows Marvell's optimistic revenue projections, expecting $20 billion by fiscal 2028 and $70-$90 billion by fiscal 2031, driven by...
